- Home
- SGU vs BCYC Comparison
SGU vs BCYC Comparison
Compare SGU & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGU | BCYC |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.6M | 438.4M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SGU | BCYC |
|---|---|---|
| Price | $11.84 | $7.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | 35.5K | ★ 293.3K |
| Earning Date | 12-08-2025 | 10-30-2025 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | ★ 102.23 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $1,784,418,000.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.44 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $11.11 | $6.03 |
| 52 Week High | $13.75 | $21.14 |
Technical Indicators
Market Signals| Indicator | SGU | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 55.07 |
| Support Level | $11.66 | $7.03 |
| Resistance Level | $12.12 | $7.65 |
| Average True Range (ATR) | 0.26 | 0.38 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 33.33 | 73.86 |
Price Performance
Historical ComparisonAbout SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.